TMO stock sentiment todayThermo Fisher Scientific Inc
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
TMO
Thermo Fisher Scientific IncThe ultimate 'picks and shovels' play for the life sciences sector, TMO is rebounding as biotech funding stabilizes and inventory destocking cycles conclude.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for TMO. Not financial advice.
Price · last 12 months
Gossip
Market sentiment has shifted from 'post-pandemic hangover' to 'recovery play.' Investors are optimistic about the recovery in the Chinese market and the easing of the funding environment for smaller biotech firms, which are key customers for TMO's high-end instrumentation.
- ·Stabilizing bioprocessing demand
- ·Anticipated interest rate cuts fueling biotech R&D spending
- ·M&A speculation following the Olink acquisition integration
Financial
TMO maintains a fortress balance sheet with high recurring revenue (approx. 80%). While top-line growth slowed post-COVID, aggressive margin management and share buybacks have kept EPS quality high.
- ·Operating Margin: ~22-24%
- ·P/E Ratio: ~28x Forward (Historical average range)
- ·Free Cash Flow: ~$7B+ annually
- ·ROIC: Consistently double-digit
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow hype — the story is loud but nobody with skin in the game is buying.
- ·Insiders sold a net $10.7M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Geopolitical exposure in China (roughly 10% of revenue)
- ·Ongoing integration risks from large-scale acquisitions
- ·Slower-than-expected recovery in pharma capital expenditure
Peer temperature
How direct competitors stack up against TMO right now.
- HOTDHRDanaher Corporation
HOTTER — trading at a premium valuation but offers higher pure-play exposure to high-margin bioprocessing compared to TMO's broader instrument mix.
See full analysis → - NEUTRALAAgilent Technologies
COLDER — lacks the massive scale and clinical trial service breadth of TMO, making it more sensitive to specific lab equipment cycles.
See full analysis → - NEUTRALIQVIQVIA Holdings
COLDER — while dominant in data/CRO services, it lacks TMO's physical 'razor-and-blade' consumable revenue model which provides a safer floor.
See full analysis →
- TMO+6.2%
- DHR+4.0%
- A+6.9%
- IQV+13.4%
Analyst price target
Consensus average of 22 analysts · median 639.00
Source: StockAnalysis.com · updated 2026-09-03
AI-generated analysis for informational purposes only. Not financial advice.